196 related articles for article (PubMed ID: 35899469)
1. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.
Papi A; Corren J; Castro M; Domingo C; Rogers L; Chapman KR; Jackson DJ; Daizadeh N; Pandit-Abid N; Gall R; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
Allergy; 2023 Jan; 78(1):233-243. PubMed ID: 35899469
[TBL] [Abstract][Full Text] [Related]
2. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
Corren J; Katelaris CH; Castro M; Maspero JF; Ford LB; Halpin DMG; Rice MS; Radwan A; Deniz Y; Rowe PJ; Teper A; Djandji M
Eur Respir J; 2021 Oct; 58(4):. PubMed ID: 34266940
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
Bourdin A; Papi AA; Corren J; Virchow JC; Rice MS; Deniz Y; Djandji M; Rowe P; Pavord ID
Allergy; 2021 Jan; 76(1):269-280. PubMed ID: 33010038
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
Bourdin A; Virchow JC; Papi A; Lugogo NL; Bardin P; Antila M; Halpin DMG; Daizadeh N; Djandji M; Ortiz B; Jacob-Nara JA; Gall R; Deniz Y; Rowe PJ
Respir Med; 2022 Oct; 202():106938. PubMed ID: 36087550
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Arima K; Miyata M; Takahashi Y; Rice MS; Deniz Y; Rowe P; Patel N; Graham NMH; Teper A
Allergol Int; 2020 Oct; 69(4):578-587. PubMed ID: 32444306
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.
Busse WW; Maspero JF; Lu Y; Corren J; Hanania NA; Chipps BE; Katelaris CH; FitzGerald JM; Quirce S; Ford LB; Rice MS; Kamat S; Khan AH; Jagerschmidt A; Harel S; Rowe P; Pirozzi G; Amin N; Ruddy M; Graham NMH; Teper A
Ann Allergy Asthma Immunol; 2020 Nov; 125(5):565-576.e1. PubMed ID: 32474156
[TBL] [Abstract][Full Text] [Related]
7. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
Busse WW; Wenzel SE; Casale TB; FitzGerald JM; Rice MS; Daizadeh N; Deniz Y; Patel N; Harel S; Rowe PJ; Graham NMH; O'Riordan T; Pavord ID
Lancet Respir Med; 2021 Oct; 9(10):1165-1173. PubMed ID: 34181876
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.
Corren J; Castro M; O'Riordan T; Hanania NA; Pavord ID; Quirce S; Chipps BE; Wenzel SE; Thangavelu K; Rice MS; Harel S; Jagerschmidt A; Khan AH; Kamat S; Maroni J; Rowe P; Lu Y; Amin N; Pirozzi G; Ruddy M; Graham NMH; Teper A
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):516-526. PubMed ID: 31521831
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose.
Pavord ID; Bourdin A; Papi A; Domingo C; Corren J; Altincatal A; Radwan A; Pandit-Abid N; Jacob-Nara JA; Deniz Y; Rowe PJ; Laws E; Lederer DJ; Hardin M
Allergy; 2023 Nov; 78(11):2921-2932. PubMed ID: 37431558
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization.
Corren J; Hanania NA; Busse WW; Sher LD; Altincatal A; Hardin M; Mannent LP; Amin N; Lederer DJ; Soler X; Jacob-Nara JA; Rowe PJ; Deniz Y
Clin Exp Allergy; 2023 Oct; 53(10):1020-1030. PubMed ID: 37752621
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.
Bleecker ER; Panettieri RA; Lugogo NL; Corren J; Daizadeh N; Jacob-Nara JA; Deniz Y; Rowe PJ; Khodzhayev A; Soler X; Ferro TJ; Hansen CN
J Immunol Res; 2023; 2023():9943584. PubMed ID: 37901346
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function.
Pavord ID; Siddiqui S; Papi A; Corren J; Sher LD; Bardin P; Langton D; Park HS; Rice MS; Deniz Y; Rowe P; Staudinger HW; Patel N; Ruddy M; Graham NMH; Teper A
J Asthma Allergy; 2020; 13():701-711. PubMed ID: 33364789
[TBL] [Abstract][Full Text] [Related]
13. Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study.
Guilbert TW; Murphy KR; Hamelmann E; Ross KR; Gupta A; Fiocchi A; Xia C; Gall R; Ledanois O; Radwan A; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2024; 17():81-87. PubMed ID: 38347908
[TBL] [Abstract][Full Text] [Related]
14. Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
Corren J; Katelaris CH; Castro M; Maspero JF; Humbert M; Halpin DMG; Altincatal A; Pandit-Abid N; Soler X; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37859672
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.
Castro M; Rabe KF; Corren J; Pavord ID; Katelaris CH; Tohda Y; Zhang B; Rice MS; Maroni J; Rowe P; Pirozzi G; Amin N; Ruddy M; Akinlade B; Graham NMH; Teper A
ERJ Open Res; 2020 Jan; 6(1):. PubMed ID: 32010719
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
Hanania NA; Castro M; Bateman E; Pavord ID; Papi A; FitzGerald JM; Maspero JF; Katelaris CH; Singh D; Daizadeh N; Altincatal A; Pandit-Abid N; Soler X; Siddiqui S; Laws E; Jacob-Nara JA; Rowe PJ; Lederer DJ; Hardin M; Deniz Y
Ann Allergy Asthma Immunol; 2023 Feb; 130(2):206-214.e2. PubMed ID: 36332763
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization.
Corren J; Jackson DJ; Casale TB; Borish L; Rabe KF; Busse WW; Maspero JF; Jackson DJ; Daizadeh N; Altincatal A; Radwan A; Khodzhayev A; Djandji M; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2023; 16():249-260. PubMed ID: 36915284
[TBL] [Abstract][Full Text] [Related]
18. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.
Pavord ID; Deniz Y; Corren J; Casale TB; FitzGerald JM; Izuhara K; Daizadeh N; Ortiz B; Johnson RR; Harel S; Djandji M; Goga L; Crikelair N; Rowe PJ; Busse WW
J Allergy Clin Immunol Pract; 2023 Apr; 11(4):1213-1220.e2. PubMed ID: 36535524
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A; Castro M; Corren J; Pavord ID; Tohda Y; Altincatal A; Pandit-Abid N; Laws E; Akinlade B; Mannent LP; Gall R; Jacob-Nara JA; Deniz Y; Rowe PJ; Lederer DJ; Hardin M
Respir Med; 2024 Apr; 224():107535. PubMed ID: 38272376
[TBL] [Abstract][Full Text] [Related]
20. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.
Papadopoulos NG; Szefler SJ; Bacharier LB; Maspero JF; Domingo C; Fiocchi A; Lee JK; Daizadeh N; Lederer DJ; Hardin M; Gall R; Djandji M; Siddiqui S; Jacob-Nara JA; Deniz Y; Rowe PJ
Allergy; 2023 Aug; 78(8):2157-2167. PubMed ID: 37059696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
